Roche discovers, develops, manufactures and markets numerous important prescription drugs that enhance people's health, well-being and quality of life. Making oral chemotherapies available to patients diagnosed with colorectal cancer will substantially improve their quality of life while maintaining a high level of care. The Cancer Research Foundation of America is a national nonprofit health organization whose mission is the prevention and early detection of cancer through scientific research and education. Each new option for colorectal cancer treatment gives patients a better chance at finding a treatment that will increase both the quality and length of their lives. The Colon Cancer Alliance is an organization of colon and rectal cancer survivors, caregivers, people with a genetic predisposition to the disease, and other individuals touched by colorectal cancer.
Colorectal cancer is the second leading cancer killer in the United States.
The Colon Cancer Alliance is committed to ending the suffering caused by cancers of the colon, rectum, appendix and anus. The impact for patients of an oral chemotherapy agent such as Xeloda in terms of convenience and cost savings could be substantial. New additions to the tools used to fight advanced colorectal cancer are certainly needed. The Foundation's tax-exempt status was granted on July 17, 1998. The goal of the Foundation is the saving of over 40,000 lives per year through public awareness initiatives that broaden the use of preventative screening, and early detection of colon and rectal cancer, and encouragement of healthier lifestyles.